Get started

MRNA

Will we finally see 200+?My analysis for MRNA On May 3rd or 4th, breakout is expected - Flag marked with thick purple lines. - Triangle marked with upper thick purple line and lower green line - Diamond (marked in green dotted lines) should drive stock into the zone marked with small purple box. - Breakout may happen at the top right corner of the purple box. It may also break out hours (maybe a day) after, and if it does, it may move according to the green arrows. - Stock should reach top of grey box before May 10th, further analysis to be done after hitting the top. I'm not a financial advisor. Follow my advice at your own risk.
NASDAQ:MRNALong
by zxmail2006
MRNA & end of the bulls?MRNA has had a few wild weeks going up from $120 to $170. I believe this could be the end of the bullishness and it may do a correction. Why do I believe this could happen? MRNA hit historic resistance of $170, after hitting that mark it began dropping. This resistance seems like it can hold. RSI is bounced off the 70 mark on the daily chart. RSI is overbought on the 4HR chart EMA's are beginning to cross over on the hour charts. This could be a tiny correction and just bounce off $160 before continuing its path to $200 so I would keep a close eye on the stock. What I am looking for right now is: 1st support - $160 2nd support - $139_$145 3rd support - $120 At this point MRNA going back down to $100 or even lower seems incredibly unlikely. Moderna's earnings arent too far away so that could act as a catalyzer that will continue the growth. In short I believe that MRNA could have hit the resistance and it will either go down to the listed supports or if it stays in these levels then it will most likely stay like this till earnings come which will tell what direction it is going to go from here. Please comment down your ideas and thoughts on this, I would appreciate any criticism you may have on the charts and analysis, and looking forward to your comments! I am not a financial advisor, these are my personal ideas an thoughts please do your own research before buying a stock.
NASDAQ:MRNAShort
by Geckie
10
Biotech Double Bottom (+ Divergence & Bollinger Reversal)Technical Analysis 1. As you see in the chart, we have tested the 200ema 3 times in the past; and it has not trade below it since April 2020. We have made a spinning-bottom on a downtrend, coincidental with a 4th test of the 200ema. 2. RSI and OBV show a positive divergence as the bottom from 2 weeks ago (Test #3) was at a lower level. 3. Bollinger Bands give us another bullish signal, as the first low (Test #3) was outside the lower BB, and the second low (Test #4) was inside the lower BB. Trade Setup A break below Test #3 which is $142.47 could be a potentially good place to set a stop-loss exit. Short-term target to the upside --> $160.5 Mid-term target to the upside --> $170 Trade with care
NASDAQ:IBBLong
by dorfmanmaster
Don't fomo into MRNA...yetMRNA made a huge leap on Friday going front $133 to $144. I believe MRNA will resume bullishnes as long as the market remains stable and bullish BUT, MRNA could drop to around $135 before continuing to go up. It still has a way to go on the RSI indicator and EMA's still haven't passed over. If MRNA exists the channel be ready for more mooning to come. Disclaimer: I am not a financial advisor and this is purely my opinion and thought about this stock, do your own research before going into MRNA.
NASDAQ:MRNA
by Geckie
4
MRNA going back down to $120?As mentioned in my last analysis, Monday will be the deal-breaker for MRNA again, and it failed to hold that resistance. Using historic data this will most likely drop down to $120 again before going back up to the $130s so this can be a great swing trade. BUT! Watch out for support at $126, using the previous downward channel trend resistance this can act as support so watch out for that. Reasons for bearishness: -Historic data of the resistance and dip (influenced the most) -EMA's crossing right now -RSI was oversold It's a clear bearish sign that probably won't last for long so look for a nice swing trade here. (I am not a financial advisor)
NASDAQ:MRNAShort
by Geckie
MRNA Moderna vs PFE Pfizer | Head and Shoulders patternIf you haven`t longed Moderna with me from here: Then you should realize that the head an shoulders pattern on descending volume of a company that worth 53.402B, but has 747Mil negative earnings for 2020, may lead to $100 per share. On the other hand, undervalued, it`s Pfizer , which has the same amazing results with the vaccine, lots of medicine in the portfolio, a market cap almost 4 times higher, 198.973B and positive earnings of 9.62Bil. The pay also great dividends, btw, 4.38% DIV YIELD on a decent 20.82 P/E ratio . If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:MRNAShort
by TopgOptions
8
MRNA Upside PotentialModerna has been forming a hidden bullish divergence for the past 5 months (clearly seen on the daily chart, will also post a screenshot in the comments). On the macro-level, we can see a pennant forming with strongly confirmed resistance and support. On the micro-level, we have a clear cup and handle, and currently the price seats at the support of the handle, in 3h demand, and also at a strong key level 135-136, that MRNA always reacted to in the past. If Moderna confirms the cup and handle by breaking the resistance, would love to add to my long position. However, if it can not hold 135-136, will look to exit and reenter at the macro support ~129. *The idea above is my own opinion and does not serve as any kind of investment advice. Please do your own due diligence.*
NASDAQ:MRNALong
by CodrinTrades
4
MRNA to 250 in MarMRNA could possibly reach as high as 250’s before or after the earnings report on 10 Mar. Not only it may beat the earnings estimate, there are also quite positive news which may lead to explosive growth. First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research NEW YORK and LA JOLLA, CA—A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, IAVI and Scripps Research announced today. The vaccine showed success in stimulating production of rare immune cells needed to start the process of generating antibodies against the fast-mutating virus; the targeted response was detected in 97 percent of participants who received the vaccine. … The study sets the stage for additional clinical trials that will seek to refine and extend the approach—with the long-term goal of creating a safe and effective HIV vaccine. As a next step, IAVI and Scripps Research are partnering with the biotechnology company Moderna to develop and test an mRNA-based vaccine that harnesses the approach to produce the same beneficial immune cells. Using mRNA technology could significantly accelerate the pace of HIV vaccine development. … The strategy of targeting naïve B cells with specific properties is called “germline-targeting,” as these young B cells display antibodies encoded by unmutated, or “germline” genes. Researchers believe the approach could also be applied to vaccines for other challenging pathogens such as influenza, dengue, Zika, hepatitis C viruses and malaria.
NASDAQ:MRNALong
by financialSnail88674
6